Pharma Exec Warns EU Transparency Push Could Delay Drug Applications

Clinical Trials Advisor
A A
If EU regulators and pharma cannot agree on how to handle publication of clinical trial data, drugmakers may delay filing applications in Europe to preserve exclusivity, a Pfizer official says.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00